Author name: Sreyoshi Guha

Thematic Highlight This fortnight’s thematic highlights were brought by Adarsh Ramanujan and our fellowship applicant, Kashish Makkar, respectively: Adarsh Ramanujan wrote an interesting guest post, throwing some much needed light on the element of “public interest” during the grant of injunctions in patent proceedings. He deconstructs the “public interest element” – taking us through the way various aspects of it are understood by both Indian and foreign courts. He concludes by suggesting ways in which parties should approach the “public

We’ve had quite an eventful fortnight at the blog: Thematic Highlight This fortnight’s thematic highlight was a guest post by our fellowship applicant, Prarthana Patnaik. Taking apart a recent US District Court judgment that held the “embedding” of tweets as copyright infringement, Prarthana discusses the implications of the decision. In doing so, she critically analyses the Court’s understanding and application of the “Server Test” – which is the landmark judicial test employed in deciding issues of copyright infringement of electronic

Topical Highlight The topical highlight for this fortnight was Rajiv’s analysis of the recent ruling of the United States Supreme Court (USSC) in the case of Oil States Energy Services v. Greene’s Energy Group, upholding the legality of the post grant review process before the Patent Trial and Appeals Board. Going over the facts and procedural history of the case, Rajiv notes that the process for post grant review was brought into American patent law by way of the ‘America Invents

The thematic highlight for this fortnight, is Rahul’s post on the recent Bombay HC judgment that held copyright registration mandatory for maintaining an action of infringement. Rahul notes the Court’s flawed reasoning that since, under section 50-A, registration is the only way to inform the public of copyright in a work, this is indicative of legislative intent to make registration mandatory. The Court also applied this reasoning to hold that several other provisions would be deemed unworkable if registration was

By way of a special report that I highly recommend to our readers, Prashant & Balaji brought us this week’s topical highlight. The report draws on a recent coverage by The Hindu reporting limited access to Bedaquiline, which has been touted to be the most promising drug for the treatment of multi-drug resistant tuberculosis (MDR-TB) and is patented by US based company, Janssen. Subsequently diverging from the Hindu report, Prashant and Balaji take us through their own research on the